Every Form 4 that NovaBay Pharmaceuticals, Inc. (NBY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NBY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NBY filings page.
Stablecoin Development Corp issued and sold pre-funded warrants to Framework Ventures IV L.P. representing the right to buy 50,109,253 shares of Common Stock. Framework paid $0.85 per warrant, and each warrant is exercisable at $0.05 per underlying share.
The pre-funded warrants have no expiration date and become exercisable on a tiered schedule: 20% on July 16, 2026, 30% on October 16, 2026, and the remaining 50% on January 16, 2027. All figures already reflect a 1-for-5 reverse stock split effective February 20, 2026. Other related Framework entities and individuals may be deemed beneficial owners to the extent of their pecuniary interest.
Stablecoin Development Corp disclosed that entities associated with Chief Executive Officer Michael John Kazley purchased pre-funded warrants giving rights to acquire 53,679,974 shares of Common Stock. The warrants were issued to R01 Fund LP at a purchase price of $0.85 per warrant, with an exercise price of $0.05 per share.
The pre-funded warrants have no expiration date and become exercisable in tiers: 20% on July 16, 2026, 30% on October 16, 2026 and the remaining 50% on January 16, 2027. The securities are held indirectly through the R01 Entities, which disclaim beneficial ownership except to the extent of their pecuniary interest, and all figures reflect a 1-for-5 reverse stock split effective February 20, 2026.
Stablecoin Development Corp director and CEO Michael John Kazley reported amended indirect holdings through the R01 Entities. The filing shows a conversion of derivative securities into 11,361,216 shares of Common Stock held indirectly and an indirect purchase of pre-funded warrants.
The pre-funded warrants, held by the R01 Entities, cover 11,332,020 shares of Common Stock at an exercise price of $0.01 per share and have no expiration date, remaining exercisable at any time. The amendment also reflects a 1-for-5 reverse stock split that adjusted prior Common Stock holdings from 56,806,080 shares to 11,361,216 shares.
Stablecoin Development Corp’s large shareholder group, including Framework Ventures IV L.P., updated its ownership to reflect a reverse stock split and warrant adjustments. The filing shows a derivative conversion into 11,361,216 shares of Common Stock and direct ownership of that amount after the transaction.
The group also holds Pre-Funded Warrants exercisable for 11,332,020 shares of Common Stock at a conversion price of $0.01 per share. The warrants were adjusted for anti-dilution protections and a 1-for-5 reverse stock split and have no expiration date, allowing exercise at any time.
Stablecoin Development Corp insider group led by R01 Fund LP reported a larger equity position through pre-funded warrants and a derivative conversion into common stock. They now hold 11,361,216 shares of Common Stock following these updates.
On October 16, 2025, the group bought 11,332,020 Pre-Funded Warrants, each exercisable into one share of Common Stock at an exercise price of $0.01 per share, with no expiration and exercisable at any time. A subsequent 1-for-5 reverse stock split effective February 20, 2026 reduced their Common Stock holdings from 56,806,080 to 11,361,216 shares and adjusted the warrants so that 56,660,098 pre-split underlying shares became 11,332,020 post-split underlying shares issuable upon exercise.
Freiman Paul E. reported acquisition or exercise transactions in this Form 4 filing.
Stablecoin Development Corp director Freiman Paul E. received a grant of 140,000 restricted stock units (RSUs). These RSUs give him the right to receive an equal number of common shares at future dates if the vesting conditions are met.
The award vests in three equal installments: one-third on February 16, 2027, another third on January 16, 2028, and the final third on January 16, 2029. This is a compensation-related equity grant, not an open-market share purchase or sale.
Zheng Yenyou reported acquisition or exercise transactions in this Form 4 filing.
Stablecoin Development Corp director Zheng Yenyou received a grant of 140,000 restricted stock units. Each unit represents a right to one share of common stock. The RSUs vest in three equal installments on February 16, 2027, January 16, 2028, and January 16, 2029, and this grant brings his reported holdings to 140,000 RSUs.
Law Tommy reported acquisition or exercise transactions in this Form 4 filing.
Stablecoin Development Corp’s Chief Financial Officer, Law Tommy, received a grant of 300,000 restricted stock units linked to the company’s common stock. These units are compensation, not an open-market purchase or sale.
The RSUs vest in three equal installments: one-third on February 16, 2027, one-third on January 16, 2028, and the final third on January 16, 2029. After this award, Tommy holds 300,000 RSUs directly.
Kazley Michael John reported acquisition or exercise transactions in this Form 4 filing.
Stablecoin Development Corp granted Chief Executive Officer Michael John Kazley a large equity compensation package in the form of restricted stock units rather than open-market share purchases.
On March 31, 2026, he received 4,118,828 time-based RSUs, which will fully vest on February 16, 2027, generally contingent on his continued employment. He was also granted 7,722,802 performance-based RSUs tied to stock price hurdles over a five-year period and a further 7,722,801 performance-based RSUs tied to digital asset net asset value hurdles over the same five-year period. Any performance-based RSUs that are earned will vest in quarterly installments over two years after the applicable performance hurdles are met, subject to a thirteen-month cliff from January 16, 2026 and continued employment.
Sit Swan reported acquisition or exercise transactions in this Form 4 filing.
Stablecoin Development Corp director Sit Swan received a grant of 140,000 restricted stock units. Each unit represents a contingent right to receive one share of common stock. All 140,000 units were reported as directly held after the grant.
The restricted stock units will vest in three equal installments: one-third on February 16, 2027, one-third on January 16, 2028, and the final one-third on January 16, 2029. This is a compensation-related equity award rather than an open-market stock purchase or sale.
NovaBay Pharmaceuticals insider David E. Lazar, previously a 10% owner, reported the automatic conversion of 39,925 shares of Series D Convertible Preferred Stock into 6,388,000 shares of common stock on October 21, 2025, at no additional cost, following the company’s annual meeting.
Earlier in October, Lazar sold his rights in 441,325 Series D shares for $9,850,000 and rights to purchase 268,750 Series E shares for an additional $2,150,000. After these steps, he no longer holds Series D Preferred Stock and directly owns 6,388,000 common shares. The filing is identified as an exit filing for him.
NovaBay Pharmaceuticals (NBY): A reporting group filed a Form 4 showing conversions into common stock and a warrant purchase tied to prior stockholder approvals. On October 21, 2025, 220,663 shares of Series D Non‑Voting Convertible Preferred converted into 35,306,080 shares of common stock and 134,375 shares of Series E Non‑Voting Convertible Preferred converted into 21,500,000 shares of common stock, following stockholder approval at the annual meeting on October 16, 2025.
The filing also reports the purchase on October 16, 2025 of pre-funded warrants to buy 2,702,703 common shares at a $0.01 exercise price, acquired at $1.10 per warrant. The warrants have no expiration and are exercisable any time after January 1, 2026, subject to stockholder approval. Following the conversions, the filing lists 56,806,080 common shares beneficially owned directly. The report is filed by more than one reporting person, with the relationship indicated as Director.
NovaBay Pharmaceuticals (NBY) reporting persons filed a Form 4 detailing a large equity change. On October 21, 2025, they acquired 56,806,080 common shares at $0 via conversions approved by stockholders on October 16, 2025: 35,306,080 from Series D Non‑Voting Convertible Preferred and 21,500,000 from Series E Non‑Voting Convertible Preferred.
Separately, on October 16, 2025, they purchased pre‑funded warrants to buy 2,702,703 common shares at a $0.01 exercise price, paying $1.10 per warrant. The warrants have no expiration and are exercisable for common stock any time after January 1, 2026, subject to stockholder approval.
NovaBay Pharmaceuticals (NBY): CEO, director and 10% owner Michael Kazley reported insider activity. On 10/21/2025, 220,663 shares of Series D Non‑Voting Convertible Preferred converted into 35,306,080 common shares, and 134,375 shares of Series E Non‑Voting Convertible Preferred converted into 21,500,000 common shares, totaling 56,806,080 common shares, held indirectly via the R01 Entities.
On 10/16/2025, R01 Fund LP purchased pre‑funded warrants to buy 2,702,703 common shares at a $1.10 purchase price per warrant with a $0.01 exercise price. These warrants have no expiration and are exercisable any time after 01/01/2026, subject to stockholder approval.
NovaBay Pharmaceuticals (NBY): Form 4/A insider update. Framework Ventures IV L.P. reported a transaction tied to preferred shares that convert into common stock following stockholder approvals at the October 16, 2025 annual meeting.
On October 9, 2025, Framework Ventures IV L.P. purchased from David Lazar 220,663 shares of Series D Non-Voting Convertible Preferred Stock and the rights and obligation to purchase 134,375 shares of Series E Non-Voting Convertible Preferred Stock. Following stockholder approvals at the meeting on October 16, 2025, each Series D and Series E preferred share converts into 160 shares of common stock. The filing lists underlying amounts of 35,306,080 common shares for the Series D and 21,500,000 common shares for the Series E. The transaction was reported with code J and a stated conversion price of $0.00.
This amendment was filed solely to add Michael Ernest Anderson as a reporting person, and the Framework entities are jointly filing pursuant to a Joint Filing Agreement.